ORPEGEN Pharma - History

1982	Foundation of ORPEGEN, predecessor of ORPEGEN Pharma.
1984	Commencement of the manufacture of amino acid derivatives and pharmaceutical peptides
1985	1985 Participation of Deutsche Shell AG as investing partner.
1985	Di-tert.butyl threonine produced up to ton quantities for insulin industry.
1987	Participation of Heidelberg Cement AG as investing partner.
1989	Contract development and production of recombinant human Erythropoietin (rhEPO) for clinical trials up to phase III, successfully completed in 1993 .
1994	EPO Project terminated due to patent debates between USA and Europe. Restructuring, ORPEGEN Pharma 100% held by Prof. Birr.
1997	BASOTEST, first quantitative diagnostic for allergies on market.
1999	GMP production of monoclonal antibodies for in-vivo diagnostics.
2001	GMP production of glycoproteins for therapy.
2002	20 years jubilee. Investment by High Tech Private Equity.
2004	Inauguration of the new multi-purpose biotechnology facility operating 4 parallel GMP modules for the manufacture of proteins in animal cells.